Thursday, March 5

6:30 p.m.-8:30 p.m.  Welcome and Opening Keynote Session: Antiangiogenesis at Crossroads
Plaza International Ballroom G
Session Co-Chairpersons: Helen Chen, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, and Rakesh K. Jain, Massachusetts General Hospital, Boston, MA

6:30  Heterogeneity of the tumor vasculature: Why doesn't anti-VEGF/VEGF receptor therapy work better?
Harold F. Dvorak, Beth Israel Deaconess Medical Center, Boston, MA

7:10  Title to be announced
Napoleone Ferrara, UC San Diego Moores Cancer Center, La Jolla, CA

7:50  Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia
Rakesh K. Jain

8:30 p.m.-10:00 p.m.  Opening Reception
Garden Terrace

Friday, March 6

7:30 a.m.-8:30 a.m.  Continental Breakfast
Plaza International Ballroom D/E/F

8:30 a.m.-10:00 a.m.  Plenary Session 1: What is Limiting the Clinical Success of Antiangiogenic Therapy?
Plaza International Ballroom G

8:30  Determination of the magnitude of clinical benefit of angiogenesis inhibitors and molecular imaging to visualize drug behavior
E. G. Elisabeth De Vries, University Medical Center Groningen, Groningen, The Netherlands

9:00  Title to be announced
Tracy T. Batchelor, Harvard Medical School, Massachusetts General Hospital, Boston, MA

9:30  Successes and challenges in antiangiogenesis therapy in gastrointestinal cancer
Eric Van Cutsem, University of Leuven, Leuven, Belgium

10:00 a.m.-10:30 a.m.  Break
Plaza International Ballroom Foyer
10:30 a.m.-12:00 p.m.  **Plenary Session 2: Biomarkers / Novel Imaging to Assess Response – Part 1**  
Plaza International Ballroom G

10:30  Title to be announced  
Carlos Bais, Genentech, Inc., South San Francisco, CA

11:00  **Biomarkers of response and resistance to antiangiogenic therapy**  
Dan G. Duda, Harvard Medical School, Boston, MA

11:30  **Genetic and epigenetic changes underlying resistance to antiangiogenic therapies**  
Diether Lambrechts, Vesalius Research Center, Leuven, Belgium

12:00 p.m.-3:00 p.m.  **Poster Session A / Lunch (provided)**  
Plaza International Ballroom D/E/F

3:00 p.m.-4:30 p.m.  **Plenary Session 3: Biomarkers / Novel Imaging to Assess Response – Part 2**  
Plaza International Ballroom G

3:00  **Angiopoietin/Tie2 as predictive biomarkers for bevacizumab in ovarian cancer**  
Gordon C. Jayson, Christie NHS Foundation Trust, Manchester, United Kingdom

3:30  **Perfusion MRI: A potential biomarker of tumor response in clinical trials**  
Kyrre E. Emblem, Oslo University Hospital, Oslo, Norway

4:00  Title to be announced  
William C. Aird, Beth Israel Deaconess Medical Center, Boston, MA

4:30 p.m.-  **Dinner on Own / Evening Off**

**Saturday, March 7**

7:30 a.m.-8:30 a.m.  **Continental Breakfast**  
Plaza International Ballroom D/E/F

8:30 a.m.-10:00 a.m.  **Plenary Session 4: Where Do We Go Beyond VEGF? – Part 1**  
Plaza International Ballroom G

8:30  Title to be announced  
Gabriele Bergers, University of California, San Francisco, CA

9:00  **Complex stromal interactions in pancreatic cancer**  
Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

9:30  **Overcoming obesity-induced resistance to anti-VEGF therapy**  
Dai Fukumura, Massachusetts General Hospital/Harvard Medical School, Boston, MA
10:00 a.m.-10:30 a.m.  Break  
Plaza International Ballroom Foyer

10:30 a.m.-12:30 p.m.  Plenary Session 5: Where Do We Go Beyond VEGF? – Part 2  
Plaza International Ballroom G

10:30  Combinatorial targeting of angiogenic growth factor pathways  
Kari K. Alitalo, University of Helsinki, Helsinki, Finland

11:00  Influence on vessel shape of macrophage metabolism in the tumor hypoxic niche  
Massimiliano Mazzone, Catholic University of Leuven, Leuven, Belgium

11:30  Title to be announced  
Herbert I. Hurwitz, Duke University Medical Center, Durham, NC

12:00  CLIC3 is secreted by CAFs and enhances angiogenesis and tumor cell invasion by cooperating with TGM2*  
Sara Zanivan, Beatson Institute for Cancer Research, Glasgow, United Kingdom

12:15  Obesity promotes resistance to anti-VEGF therapy in breast cancer via pro-inflammatory and angiogenic pathways*  
Joao Incio, Harvard Medical School, Boston, MA

12:30 p.m.-2:30 p.m.  Free Time / Lunch on Own

2:30 p.m.-4:00 p.m.  Plenary Session 6: Combining Antiangiogenesis and Immunotherapies  
Plaza International Ballroom G

2:30  Immune checkpoint blockade in cancer therapy: New insights and opportunities  
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00  Antiangiogenesis plus immune checkpoint blockade for the treatment of cancer  
F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA

3:30  CXCR4 inhibition reverts immunosuppressive tumor microenvironment and facilitates anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma*  
Rakesh Ramjiawan, Massachusetts General Hospital, Charlestown, MA

3:45  Intravital imaging of cytolytic activity reveals how poor tumor vascularization and hypoxia limit tumor rejection*  
Guy Shakhar, Weizmann Institute of Science, Rehovot, Israel

4:00 p.m.-6:30 p.m.  Poster Session B / Reception  
Plaza International Ballroom D/E/F

6:30 p.m.-  Dinner on Own/Evening Off

*Short talks from proffered papers.
**Sunday, March 8**

7:30 a.m.-8:30 a.m.  **Continental Breakfast**  
Plaza International Ballroom Foyer

8:30 a.m.-10:00 a.m.  **Plenary Session 7: Why is Antiangiogenesis Not Efficacious in Early Disease Setting?**  
Plaza International Ballroom G

8:30  **Vascular phenotyping: Using genomics to inform antiangiogenesis**
Laura E. Benjamin, ImClone Systems, New York, NY

9:00  **Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes**  
Robert S. Kerbel, Sunnybrook Research Institute, Toronto, ON, Canada

9:30  **An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab**
Wei Wei, Massachusetts General Hospital, Boston, MA

9:45  **Formation of lymph node metastases is not angiogenesis dependent**
Timothy P. Padera, Massachusetts General Hospital, Boston, MA

10:00 a.m.-10:15 a.m.  **Break**  
Plaza International Ballroom Foyer

10:15 a.m.-11:45 a.m.  **Closing Keynote Session: Antiangiogenesis: Safety Issues and Endothelial Metabolism**  
Plaza International Ballroom G  
*Session Chairpersons: Peter Carmeliet, Vesalius Research Center, Leuven, Belgium, and Helen Chen, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD*

10:15  **Angiogenesis revisited: Principles and strategies**  
Peter Carmeliet

11:00  **Tolerability of antiangiogenic therapies and novel combinations: Search for the optimal therapeutic window**  
Helen Chen

11:45 a.m.  **Departure**

*Short talks from proffered papers.

**Not designated for CME credit.